Invokana Leads

Invokana belongs to a newer class of Type 2 diabetes treatments called sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of medication that works by stopping glucose from being reabsorbed into the blood. The FDA warned Invokana can also cause ketoacidosis, a condition that requires hospitalization and can cause fatal swelling of the brain, severe dehydration and coma.

Number of Lawsuits

About 990 in the Invokana MDL; 57 in the Farxiga MDL

Plaintiff Injuries

Diabetic ketoacidosis, kidney damage and others

Defendants

Johnson & Johnson’s Janssen Pharmaceuticals subsidiary, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim and Eli Lilly

Litigation Status

Active

Federal, State and Class-Action Lawsuits

SGLT2 drug lawsuits are in their early stages and have not yet proceeded to trial or been part of any large settlements. But the cases involving about 800 plaintiffs who say the drugs caused injuries are proceeding on several fronts:

Clarkson S. Fisher Federal Courthouse, site of the Invokana New Jersey MDL

Site of the Invokana New Jersey MDL 

Clarkson S. Fisher Federal Courthouse, site of the Invokana New Jersey MDL


According to Johnson & Johnson, there are also federal lawsuits over Invokana pending in federal court in California and Missouri. There are also cases in state courts in Pennsylvania, California and New Jersey.

U.S. District Judge Lorna G. Schofield is overseeing a Farxiga MDL in the Southern District of New York. As of Dec. 18, 2017, there were 55 cases pending in the Farxiga MDL.

invokana lead management

515 E Las Olas Blvd #120, Fort Lauderdale, FL 33301

E: leads@classactionleads.com
P: 954-234-1055

Interested In Invokana Leads?

We are open from 9am — 7pm week days.

Lead Order Placed
Lead Package Update